BRAF and melanoma: To identify regulators of metabolic response following treatment with oncogene targeted therapy, we performed a genome-wide RNAi screen using BRAFV600 melanoma cells treated with the BRAF inhibitor (BRAFi) vemurafenib (Vem) as a paradigm (Fig. 1a)17.